Condition: Central Nervous System Lymphoma · Sponsor: Henan Cancer Hospital
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.
This description comes directly from the study's public registry record.
Zhihua Yao, M.D. Ph.D · +8613592622292 · zlyyyaozhihua1260@zzu.edu.cn
Yanyan Liu, M.D. Ph.D · +8613838176375 · yyliu@zzu.edu.cn
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05209620